Who is sponsoring NCT04000139?

NCT04000139 is sponsored by University of Zurich.

What drugs are being tested in NCT04000139?

Interventions in NCT04000139: Standardized anthocyanin-rich extract, Placebo.

What condition does NCT04000139 study?

NCT04000139 studies Ulcerative Colitis.

Is NCT04000139 still recruiting?

NCT04000139 is currently completed. Last updated 11 May 2021.

Last reviewed 2021-05-11 · How we verify

NCT04000139: ACRE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anthocyanin Rich Extract (ACRE) in Patients With Ulcerative Colitis

Completed Phase 2 Last updated 11 May 2021

What this trial tests

Phase 2 trial testing Standardized anthocyanin-rich extract in Ulcerative Colitis in 48 participants. Completed in 11 March 2021.

Timeline

1 April 2019

Primary endpoint
11 March 2021

11 March 2021

Quick facts

Lead sponsor	University of Zurich
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	48
Start date	1 April 2019
Primary completion	11 March 2021
Estimated completion	11 March 2021
Sites	6 locations across Switzerland

Drugs / interventions tested

Standardized anthocyanin-rich extract — full drug profile →
Placebo

Conditions studied

Ulcerative Colitis — all drugs for Ulcerative Colitis →

Sponsor

University of Zurich

Who can join

18 and older, any sex, with Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the efficacy and safety of a bilberry derived anthocyanin-rich extract in patients with ulcerative colitis. Two thirds of participants will receive the anthocyanin-rich extract, while one third will receive placebo, for 8 weeks of treatment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Natural compounds as safe therapeutic options for ulcerative colitis.
Gupta M, Mishra V, Gulati M, Kapoor B, et al · · 2022 · cited 55× · PMID 35212849 · DOI 10.1007/s10787-022-00931-1
Exploring the Impact of Cyanidin-3-Glucoside on Inflammatory Bowel Diseases: Investigating New Mechanisms for Emerging Interventions.
Frountzas M, Karanikki E, Toutouza O, Sotirakis D, et al · · 2023 · cited 15× · PMID 37298350 · DOI 10.3390/ijms24119399
Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial.
Biedermann L, Doulberis M, Schreiner P, Nielsen OH, et al · · 2024 · cited 4× · PMID 39683589 · DOI 10.3390/nu16234197

Verify or expand the search:

Other recruiting trials for Ulcerative Colitis

Currently open trials in the same condition.

NCT07185009 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
NCT07265570 — Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) · Phase 2 · recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
NCT07184996 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting

Other University of Zurich trials

Trials by the same sponsor.

NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04000139 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Zurich
Last refreshed: 11 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04000139.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing